STOCK TITAN

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

ProMIS Neurosciences announced Q3 2024 financial results and recent highlights. The company reported positive results from its Phase 1a clinical trial of PMN310 for Alzheimer's disease, showing the drug was well-tolerated with monthly dosing and demonstrated potential target engagement. Cash position stood at $21.5 million as of September 30, 2024. The company completed a PIPE financing with $30.3 million upfront and potential for additional $92.4 million from warrant exercises. Q3 showed net income of $9.3 million, primarily due to warrant liability changes. R&D expenses increased to $2.6 million, mainly for PMN310 clinical trials.

ProMIS Neurosciences ha annunciato i risultati finanziari del terzo trimestre del 2024 e i recenti sviluppi. L'azienda ha riportato risultati positivi dal suo trial clinico di Fase 1a su PMN310 per il morbo di Alzheimer, dimostrando che il farmaco è stato ben tollerato con dosaggi mensili e ha mostrato un potenziale coinvolgimento del target. La posizione cash si è attestata a $21,5 milioni al 30 settembre 2024. L'azienda ha completato un finanziamento PIPE con $30,3 milioni iniziali e potenzialità per ulteriori $92,4 milioni da esercizi di warrant. Il terzo trimestre ha mostrato un reddito netto di $9,3 milioni, principalmente a causa delle variazioni della passività dei warrant. Le spese per R&D sono aumentate a $2,6 milioni, principalmente per le sperimentazioni cliniche di PMN310.

ProMIS Neurosciences anunció los resultados financieros del tercer trimestre de 2024 y los aspectos destacados recientes. La compañía reportó resultados positivos de su ensayo clínico de Fase 1a de PMN310 para la enfermedad de Alzheimer, mostrando que el medicamento fue bien tolerado con dosificación mensual y demostró un potencial compromiso objetivo. La posición de efectivo se situó en $21.5 millones hasta el 30 de septiembre de 2024. La empresa completó un financiamiento PIPE con $30.3 millones por adelantado y un potencial adicional de $92.4 millones de ejercicios de warrants. El tercer trimestre mostró un ingreso neto de $9.3 millones, principalmente debido a cambios en la responsabilidad de los warrants. Los gastos de I+D aumentaron a $2.6 millones, principalmente para los ensayos clínicos de PMN310.

ProMIS Neurosciences는 2024년 3분기 재무 결과 및 최근 발표된 사항을 보고했습니다. 이 회사는 알츠하이머병에 대한 PMN310의 1a상 임상 시험에서 긍정적인 결과를 보고했으며, 월별 투여로 약물이 잘 견디고 목표 개입 가능성을 보여주었습니다. 현금 보유액은 2024년 9월 30일 기준 $21.5 백만입니다. 이 회사는 $30.3 백만의 선납금과 함께 추가로 $92.4 백만의 워런트 행사 가능성이 있는 PIPE 자금을 완료했습니다. 3분기 순이익은 $9.3 백만으로, 주로 워런트 책임 변동 때문입니다. 연구개발(R&D) 비용은 $2.6 백만으로 증가했으며, 주로 PMN310 임상 시험을 위한 것입니다.

ProMIS Neurosciences a annoncé les résultats financiers du troisième trimestre 2024 ainsi que les principales réalisations récentes. L'entreprise a rapporté des résultats positifs de son essai clinique de Phase 1a pour PMN310 concernant la maladie d'Alzheimer, montrant que le médicament était bien toléré avec une posologie mensuelle et démontrait un potentiel d'interaction avec la cible. La position de liquidités s'élevait à 21,5 millions de dollars au 30 septembre 2024. L'entreprise a complété un financement PIPE avec 30,3 millions de dollars à l'avance et a la possibilité de lever un supplément de 92,4 millions de dollars grâce à des exercices de warrants. Le troisième trimestre a montré un bénéfice net de 9,3 millions de dollars, principalement dû aux variations de la responsabilité des warrants. Les dépenses en R&D ont augmenté à 2,6 millions de dollars, principalement pour les essais cliniques de PMN310.

ProMIS Neurosciences hat die Finanzergebnisse für das dritte Quartal 2024 und aktuelle Höhepunkte bekannt gegeben. Das Unternehmen berichtete von positiven Ergebnissen aus seiner Phase 1a-Studie zu PMN310 bei Alzheimer, wobei festgestellt wurde, dass das Medikament bei monatlicher Dosierung gut vertragen wurde und potenziellen Zielengagement zeigte. Die Liquiditätsposition betrug zum 30. September 2024 $21,5 Millionen. Das Unternehmen schloss eine PIPE-Finanzierung mit $30,3 Millionen im Voraus ab und hatte das Potenzial für weitere $92,4 Millionen aus der Ausübung von Warrants. Im dritten Quartal wurde ein Nettoergebnis von $9,3 Millionen erzielt, hauptsächlich aufgrund von Änderungen der Haftung aus Warrants. Die F&E-Ausgaben stiegen auf $2,6 Millionen, hauptsächlich für die klinischen Studien zu PMN310.

Positive
  • Successful completion of Phase 1a trial showing PMN310 was well-tolerated
  • Strong financial position with $21.5M cash on hand
  • Secured $30.3M PIPE financing with potential additional $92.4M
  • Reported Q3 net income of $9.3M
  • On track to initiate Phase 1b trial by end of 2024
Negative
  • R&D expenses increased to $2.6M from $1.1M year-over-year
  • G&A expenses increased to $1.9M from $1.4M year-over-year

Insights

The Q3 2024 results reveal significant financial developments for ProMIS Neurosciences. The company's cash position strengthened to $21.5 million, up from $12.6 million at 2023 year-end, bolstered by a substantial PIPE financing that brought in $30.3 million upfront with potential for additional $92.4 million from warrant exercises. The quarter showed increased R&D expenses of $2.6 million, reflecting investment in clinical trials. Despite higher operational costs, the company reported net income of $9.3 million, primarily due to a $17.0 million gain from warrant liability valuation changes. The robust financing provides runway for advancing PMN310's clinical development.

The Phase 1a trial results for PMN310 demonstrate promising clinical progress. Key findings include favorable safety profile, successful blood-brain barrier penetration and CSF levels suggesting potential target engagement. The monthly dosing schedule appears feasible based on pharmacokinetics data. The upcoming Phase 1b trial in 100 AD patients represents a important next step in clinical development. PMN310's selective binding to toxic amyloid-beta oligomers differentiates it in the competitive AD treatment landscape. The preclinical vaccine program data showing maximal reactivity against epitope 301 further validates the company's therapeutic approach.

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential target engagement in patients with Alzheimer’s disease

On track to initiate Phase 1b clinical trial in patients with Alzheimer’s disease by end of 2024

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update.

“We made significant progress in the third quarter, highlighted by the positive results from our first-in-human Phase 1a clinical trial of PMN310 and the closing of a strong equity financing that could provide up to $122.7 million to advance our pipeline of neurodegenerative product candidates,” said Neil Warma, CEO of ProMIS Neurosciences. “Results from our Phase 1a study showed that PMN310 was generally safe and well-tolerated and achieved concentrations in the cerebrospinal fluid (CSF) indicating its potential for target engagement in AD patients. Additionally, these results have confirmed the dosing levels for the planned multiple ascending dose Phase 1b clinical trial in 100 patients with mild cognitive impairment due to AD and early AD, which is on track to start by the end of 2024.”

“These early clinical outcomes reinforce our confidence in PMN310's unique therapeutic profile and the impact it may have on AD patients, their families, and healthcare providers,” added Mr. Warma. “As toxic oligomers are recognized as key drivers of AD progression, we believe PMN310’s selective binding to these oligomers differentiates it from other drugs currently on the market or in development and strengthens the case for its continued advancement and positioning as a promising option in the AD treatment landscape.”

Recent Highlights

Alzheimer’s Disease Program (PMN310)

ProMIS’ lead candidate, PMN310, is a humanized IgG1 antibody directed toward toxic amyloid-beta (Ab) oligomers (AβO) that are believed to be a major driver of Alzheimer’s disease (AD).

  • The Phase 1a clinical trial was a randomized, double-blind, placebo-controlled trial in healthy normal volunteers (NCT06105528). The trial consisted of five single-ascending dose (SAD) cohorts and was designed to evaluate the safety, tolerability, and pharmacokinetics (PK), of intravenous doses of PMN310. The trial completed enrollment of all 40 subjects across two active sites in the United States. The trial was initiated based on encouraging nonclinical studies of PMN310 that support the selective targeting of AβOs.

  • In October 2024, ProMIS presented positive data from all five cohorts in its first-in-human Phase 1a clinical trial of PMN310 in healthy volunteers at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, which took place from October 29 – November 1, 2024, in Madrid, Spain. The results showed PMN310 was generally well-tolerated in all five SAD cohorts (2.5, 5, 10, 20 and 40 mg/kg) of the Phase 1a clinical trial and, importantly, crossed the blood brain barrier in healthy volunteers in a dose dependent manner with PK suggesting that monthly dosing may provide levels of PMN310 adequate for target engagement in AD patients. The complete dataset from all five cohorts reinforces previously reported data from the first four cohorts of the Phase 1a trial announced in July 2024.

  • ProMIS is on-track to initiate its PMN310 Phase 1b clinical trial by year-end 2024.

ProMIS continues to advance its Ab vaccine program in AD based on its oligomer target epitope(s).

  • In July 2024, the Company presented preclinical data in a poster at the Alzheimer’s Association International Conference (AAIC), which took place from July 29-August 1, 2024, in Philadelphia. The poster titled, “Novel approach to optimization of Alzheimer’s vaccine configuration for maximal targeting of toxic amyloid-beta oligomers,” highlighted data demonstrating that maximal reactivity was observed with immune IgG against the monovalent vaccine containing epitope 301, the target of PMN310.

Amyotrophic Lateral Sclerosis Disease Program (PMN267)

PMN267 is a humanized IgG1 antibody directed against toxic misfolded TDP-43 as a potential therapeutic target for amyotrophic lateral sclerosis (ALS).

  • In August 2024, ProMIS announced the publication of two papers highlighting the role of toxic misfolded superoxide dismutase-1 (SOD1) aggregates in the pathogenesis of ALS. One paper published in Acta Neuropathologica is titled, “Seeding activity of human superoxide dismutase 1 aggregates in familial and sporadic amyotrophic lateral sclerosis postmortem neural tissues by real-time quaking-induced conversion,” and the other paper published in the online journal, Open Biology, is titled, “Amyloidogenic regions in beta-strands II and III modulate the aggregation and toxicity of SOD1 in living cells.” The Acta Neuropathologica publication can be accessed here, and the Open Biology publication can be accessed here.

Corporate

  • In July 2024, ProMIS completed a private investment in public equity (PIPE) financing that may provide up to $122.7 million in gross proceeds, which includes an initial upfront funding of $30.3 million and up to $92.4 million tied to exercise of warrants based on the Company achieving certain milestones. The PIPE financing included participation from new and existing healthcare specialist investors such as Great Point Partners, LLC, Armistice Capital, Ally Bridge Group, Sphera Healthcare, and other institutional and individual accredited investors. Proceeds from the private placement are expected to be used to advance the clinical development of PMN310, as well as for working capital and other general corporate expenses.

Third Quarter 2024 Financial Highlights

  • Cash and cash equivalents were $21.5 million as of September 30, 2024, compared to $12.6 million as of December 31, 2023. During the quarter, the Company completed a PIPE financing that provided initial upfront funding of $30.3 million, and which has the potential to provide an additional $92.4 million tied to the potential exercise of warrants.

  • Research and development expenses were $2.6 million for the three months ended September 30, 2024, compared to $1.1 million for the same period in 2023. The increase was primarily attributable to costs related to the execution of the PMN310 Phase 1a clinical trial and preparation for the PMN310 Phase 1b clinical trial.

  • General and administrative expenses increased to $1.9 million for the quarter ended September 30, 2024, compared to $1.4 million for the same period in 2023.

  • Net income was $9.3 million for the quarter ended September 30, 2024, compared to a net loss of $2.4 million for the same period in 2023. The increase in net income was primarily attributable to a gain on the change in fair value of our warrant liabilities of $17.0 million.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company’s lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic Aβ oligomers and to not bind plaque or monomers.  ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.

Forward-Looking Statements

Nasdaq has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, ‎‎“forward-looking information”) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the ‎use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “excited about”, “an opportunity exists”, ‎‎“is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and ‎phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be ‎achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or ‎circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the announcement of results of all five cohorts of the Company’s Phase 1a study, plans to advance PMN310 into a Phase 1b study in AD patients by year-end 2024 and expectations of such study results, the potential for such studies to provide the first proof-of-concept data for PMN310, the potential that PMN310 has the potential to positively benefit patients with AD, the targeting of toxic misfolded proteins in neurodegenerative diseases that the Company believes may directly address fundamental AD pathology (including the belief and understanding that toxic oligomers of Aβ are a major driver of AD) and have greater therapeutic potential due to reduction of off-target activity, a computationally-derived Aβ vaccine for AD and the Company’s PMN310 antibody and vaccine candidate, management’s belief that its patented platform technology has created an antibody candidate specific to toxic misfolded oligomers known to be present in AD, therapeutic activity and preferential targeting of toxic soluble aggregates by Aß-directed antibodies and the potential implications thereof, the Company’s pipeline, including application of its platform to other diseases, statements regarding preclinical data, the ability to continue its growth and realize the anticipated contribution of the members of its board of directors and executives to its operation and progress, use of capital expenses, including the use of proceeds from the PIPE financing, future accumulated deficit and other financial results in the future, ability to fund operations, the ability to maintain enough liquidity to execute its business plan and its ability to continue as a going concern. Statements containing forward-looking information are not historical facts but instead represent management's current ‎expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events ‎and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to ‎known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, ‎performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk that preclinical results or early results may not be indicative of future results, the Company’s ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the “Risk Factors” section of the Company's most recently filed Annual Report on Form 10-K for the year ended December 31, 2023 and in its subsequent filings filed with the United States Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

For further information:

Visit us at www.promisneurosciences.com

Please submit media inquiries to info@promisneurosciences.com

For Investor Relations, please contact:
Precision AQ (formerly Stern IR)
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200

PROMIS NEUROSCIENCES INC.

Condensed Consolidated Balance Sheets

(expressed in US dollars, except share amounts)
(unaudited)

        
  September 30,  December 31,  
     2024     2023  
Assets       
Current assets:       
Cash $21,536,898  $12,598,146  
Short-term investments  32,358   32,358  
Prepaid expenses and other current assets  2,941,279   988,641  
Total current assets  24,510,535   13,619,145  
Total assets $24,510,535  $13,619,145  
Liabilities and Shareholders' Equity          
Current liabilities:         
Accounts payable $1,575,235  $7,843,136  
Accrued liabilities  1,059,852   1,506,526  
Total current liabilities  2,635,087   9,349,662  
Share-based compensation liability  340,090   422,002  
Warrant liability  14,262,138   94,185  
Total liabilities  17,237,315   9,865,849  
        
Commitments and contingencies         
Shareholders' equity:         
Series 2 Convertible Preferred Shares, no par value, unlimited shares authorized, 0 and 1,166,667 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively       
Common shares, no par value, unlimited shares authorized, 32,689,190 and 18,885,254 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively       
Additional paid-in capital  98,093,270   97,590,426  
Accumulated other comprehensive loss  (371,184)  (371,184) 
Accumulated deficit  (90,448,866)  (93,465,946) 
Total shareholders' equity  7,273,220   3,753,296  
Total liabilities and shareholders' equity $24,510,535  $13,619,145  

PROMIS NEUROSCIENCES INC.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(expressed in US dollars, except share amounts)
(unaudited)

              
  For the For the For the For the 
  Three Months Ended  Three Months Ended  Nine Months Ended  Nine Months Ended  
  September 30,  September 30,  September 30,  September 30,  
     2024     2023     2024     2023  
Operating expenses:             
Research and development $2,563,774  $1,142,160  $6,313,373  $5,658,127  
General and administrative  1,870,903   1,375,380   4,511,660   4,729,969  
Total operating expenses  4,434,677   2,517,540   10,825,033   10,388,096  
Loss from operations  (4,434,677)  (2,517,540)  (10,825,033)  (10,388,096) 
              
Other income (expense):             
Change in fair value of financial instruments  16,969,126   119,019   17,014,080   683,568  
Interest expense     (75,413)  (76,775)  (124,595) 
Other income  235,912   113,286   399,344   197,070  
Loss on issuance of common shares, warrants, and pre-funded warrants in July 2024 PIPE  (3,494,536)     (3,494,536)    
Total other income (expense), net  13,710,502   156,892   13,842,113   756,043  
              
Net income (loss)  9,275,825   (2,360,648)  3,017,080   (9,632,053) 
Other comprehensive income (loss)                 
Foreign currency translation adjustment           (175,815) 
Comprehensive income (loss) $9,275,825  $(2,360,648) $3,017,080  $(9,807,868) 
              
Net income (loss) per share, basic $0.31  $(0.19) $0.13  $(0.98) 
Net income (loss) per share, diluted $0.31  $(0.19) $0.13  $(0.98) 
              
Weighted-average shares outstanding of common shares, basic  30,023,675   12,370,830   22,953,751   9,861,719  
Weighted-average shares outstanding of common shares, diluted  30,067,095   12,370,830   23,676,104   9,861,719  

FAQ

What were ProMIS Neurosciences (PMN) Q3 2024 financial results?

ProMIS reported net income of $9.3M, cash position of $21.5M, R&D expenses of $2.6M, and G&A expenses of $1.9M for Q3 2024.

What were the Phase 1a trial results for PMN310?

The Phase 1a trial showed PMN310 was generally well-tolerated across all five SAD cohorts and demonstrated CSF levels indicating potential target engagement in Alzheimer's patients.

How much funding did ProMIS (PMN) secure in their PIPE financing?

ProMIS secured $30.3M in initial upfront funding with potential for additional $92.4M through warrant exercises, totaling up to $122.7M.

When will ProMIS (PMN) begin their Phase 1b trial for PMN310?

ProMIS is on track to initiate the Phase 1b clinical trial for PMN310 by the end of 2024.

ProMIS Neurosciences Inc. Common Shares (ON)

NASDAQ:PMN

PMN Rankings

PMN Latest News

PMN Stock Data

29.29M
29.89M
44.78%
30.81%
0.46%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
TORONTO